Psyence Biomedical (PBM) Assets Average (2023 - 2026)
Psyence Biomedical (PBM) posted Assets Average of $15.2 million for Q1 2026, up 50.93% on a QoQ basis from $10.1 million in Q3 2025, and up 217.43% year-over-year from $4.8 million in Q1 2025.
Analysis
Psyence Biomedical (PBM) Assets Average (2023 - 2026) Analysis & Trends
Psyence Biomedical has reported Assets Average for 4 years, with the latest figure at $15.2 million in Q1 2026.
- On a quarterly basis, Assets Average rose 217.43% year-over-year to $15.2 million in Q1 2026; TTM through Mar 2026 was $15.2 million, a 217.43% increase from a year earlier, with the FY2026 full-year figure at $12.4 million, up 194.53% from the prior year.
- Assets Average was $15.2 million for Q1 2026 at Psyence Biomedical, up from $10.1 million in the prior quarter.
- The five-year high for Assets Average was $130.3 million in Q1 2023, with the low at $1.9 million in Q3 2024.
- Average Assets Average over 4 years is $25.2 million, with a median of $7.1 million recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Assets Average plunged 94.52% in 2024, then soared 422.68% in 2025.
- Over 4 years, Assets Average stood at $7.1 million in 2023, then slumped by 73.02% to $1.9 million in 2024, then jumped by 422.68% to $10.1 million in 2025, then surged by 50.93% to $15.2 million in 2026.
- The last three Assets Average figures came in at $15.2 million (Q1 2026), $10.1 million (Q3 2025), and $4.8 million (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.64 Bn | 192.65 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.82 Bn | 176.65 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 131.16 Bn | 123.31 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.67 Bn | 73.67 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.91 Bn | 48.77 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.05 Bn | 29.05 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Psyence Biomedical | 2.65 Mn | 2.65 Mn | - | 15.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 15.19 Mn |
| Sep 30, 2025 | 10.06 Mn |
| Mar 31, 2025 | 4.78 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 7.14 Mn |
| Sep 30, 2023 | 7.14 Mn |
| Mar 31, 2023 | 130.26 Mn |